Fractyl Health

Q2 FY2026 EarningsQ2 FY26 results for GUTS were mixed relative to consensus: GAAP EPS of -$0.16 missed the -$0.13 mean estimate, driven by non-cash warrant liability adjustments, while operating loss of -$19.1M was narrower than the expected -$21.4M EBIT loss due to disciplined R&D spending. The company reported zero revenue, in-line with its clinical-stage status. Management reiterated a cash runway into early 2027 and confirmed pivotal REMAIN-1 data readout remains on track for early Q4 2026.